Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

• Morris E Feldman,

  Affiliation Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

  ⨯
• Beth Apsel,

  Affiliation Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

  ⨯
• Aino Uotila,

  Affiliation Department of Molecular Biology, University of Geneva, Switzerland

  ⨯
• Robbie Loewith,

  Affiliation Department of Molecular Biology, University of Geneva, Switzerland

  ⨯
• Zachary A Knight,

  ¤ Current address: The Rockefeller University, New York, New York, United States of America

  Affiliation Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

  ⨯
• Davide Ruggero,

  Affiliation School of Medicine and Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, United States of America

  ⨯
• Kevan M Shokat

  *To whom correspondence should be addressed. E-mail: shokat@cmp.ucsf.edu

  Affiliation Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

  ⨯